Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients

被引：0
|
作者：
Ramchandren, Sindhu
Guptill, Jeff
Antozzi, Carlo
Bril, Vera
Gamez, Josep
Meuth, Sven
Nowak, Richard
Quan, Dianna
Mantecon, Maria Teresa Sevilla
Ling, Leona
Zhu, Yaowei
Karcher, Keith
Sun, Hong
机构：
来源：
NEUROLOGY | 2022年 / 99卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
下载
收藏
页码：S35 / S37
页数：5
相关论文
共 32 条
  • [31] Improvement of wasting by treatment with a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, MRA in multicentric Castleman's disease. A phase II clinical trial of 28 patients.
    Nishimoto, N
    Kanakura, Y
    Aozasa, K
    Johkoh, T
    Nakano, N
    Nakamura, M
    Ikeda, Y
    Sasaki, T
    Nishioka, K
    Hara, M
    Taguchi, H
    Kimura, Y
    Kato, Y
    Kishimoto, T
    Yoshizaki, K
    BLOOD, 2002, 100 (11) : 202A - 203A
  • [32] TNF blockade by the fully human monoclonal antibody, adalimumab (D2E7), in the ARMADA trial results in decreases in serum matrix metalloproteinase (MMP) levels along with impressive clinical improvement in refractory RA patients.
    Furst, D
    Keystone, E
    Weinblatt, M
    Kavanaugh, A
    Weisman, M
    Fischkoff, S
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S215 - S215
1234